Verona posts sales figures for Q4 and 2024 (VRNA:NASDAQ)
Jan 7, 2025 · Verona Pharma (VRNA) stock in focus as company reports early sales for Q4 and 2024 thanks to its lung disease therapy Ohtuvayre. Read more here.
OFF
Verona Pharma Reports Approximately $36 Million In Q4 2024 Net …
2 weeks from now
Jan 7, 2025 · Verona Pharma reports $36M in Q4 and $42M in 2024 sales for Ohtuvayre, with over 16,000 prescriptions filled. Quiver AI Summary Verona Pharma plc has announced its …
nasdaq.com
OFF
Verona Pharma Reports Strong Ohtuvayre™ Launch And Provides …
2 weeks from now
Jan 7, 2025 · Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectivelyMore than 3,500 un...
businessinsider.com
OFF
Verona Pharma Reports Approximately $36 Million In Q4 2024 Net …
2 weeks from now
Jan 7, 2025 · In the fourth quarter of 2024, Verona Pharma announced an estimated net product sales of around $36 million, a significant increase from $0 million in Q4 2023. These sales …
wallstreetwaves.com
OFF
Verona Pharma Reports Approximately $36 Million In Q4 2024 Net …
2 weeks from now
Jan 7, 2025 · Net product sales for Ohtuvayre reached approximately $36 million in Q4 2024 and $42 million for the full year, indicating a strong market entry. Over 16,000 prescriptions were …
quiverquant.com
OFF
Verona Pharma Sees Q4 Net Product Sales Revenue $36M Vs. $0M A …
2 weeks from now
Jan 7, 2025 · Consensus for Q4 revenue is $12.94M. Expects to report cash and cash equivalents at December 31, 2024, of $400M vs. $271.8M a year ago. “2024 was another …
nasdaq.com
OFF
Verona Posts Early Sales Figures For Q4 And 2024
2 weeks from now
The company also reported $400M in cash as of December 31, 2024, up from $271.8M, and announced a $100M equity offering with Jefferies in Q4. Citing preliminary unaudited results …
longportapp.com
OFF
Verona Pharma's COPD Drug Ohtuvayre Hits $36M In Q4 Sales, …
2 weeks from now
Jan 7, 2025 · Verona Pharma reports strong performance for their newly launched COPD treatment Ohtuvayre (ensifentrine), with approximately $36 million in net product sales for Q4 …
stocktitan.net
OFF
Verona Pharma Expects Preliminary Q4 Sales Of About $36 Mln …
2 weeks from now
Jan 7, 2025 · (RTTNews) - Verona Pharma plc (VRNA), a biopharmaceutical company, Tuesday announced that the company expects preliminary unaudited fourth quarter net product sales of …
nasdaq.com
OFF
Verona Pharma Reports Strong Ohtuvayre Launch And Provides …
2 weeks from now
Jan 8, 2025 · Product sales: The Company expects to report that net product sales were approximately $36 million for the fourth quarter ended December 31, 2024 (Q4 2023: $0 …
marketscreener.com
OFF
Verona Pharma To Report $36 Million In Q4 Net Product Revenue
2 weeks from now
Jan 7, 2025 · -- Verona Pharma on Tuesday said it expects Q4 net product sales of $36 million on the back of the commercial launch of Ohtuvayre, a treatment for chronic obstructive pulmonary …
marketscreener.com
OFF
Verona Pharma Soars 4.6% On Strong Q4 Sales: What
2 weeks from now
Jan 7, 2025 · Verona Pharma (NASDAQ: VRNA) shines with strong Q4 sales for its lung disease treatment, Ohtuvayre, lifting shares by 4.6% in premarket. With $400 million in cash, the …
stockinvest.us
OFF
Verona Pharma Price Target Raised To $74 From $64 At Wells Fargo
2 weeks from now
Jan 8, 2025 · Wells Fargo analyst Tiago Fauth raised the firm’s price target on Verona Pharma (VRNA) to $74 from $64 and keeps an Overweight rating on the shares. The firm notes …
nasdaq.com
FAQs about Verona posts sales figures for Q4 and 2024 (VRNA:NASDAQ) Coupon?
How did Verona Pharma perform in Q4?
Why did Verona launch ohtuvayre in 2024?
What does Verona Pharma do?
Install CouponFollow Extension on Chrome
Install the CouponFollow extension to search for discount codes when shopping the fastest!
Install CouponFollow Chrome Extension
Listing Store by Characters
